Arcellx, Inc. (ACLX)

Market Cap	4.72B
Revenue (ttm)	155.82M
Net Income (ttm)	-40.42M
Shares Out	54.07M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	332,625
Open	86.87
Previous Close	87.59
Day's Range	83.69 - 88.30
52-Week Range	46.42 - 107.37
Beta	0.27
Analysts	Strong Buy
Price Target	103.67 (+18.86%)
Earnings Date	Nov 7, 2024

About ACLX

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treatin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2022
• Employees: 130
• Stock Exchange: NASDAQ
• Ticker Symbol: ACLX
• Website: https://www.arcellx.com

Analyst Forecast

According to 14 analysts, the average rating for ACLX stock is "Strong Buy." The 12-month stock price forecast is $103.67, which is an increase of 18.86% from the latest price.

Price Target

$103.67

(18.86% upside)

Analyst Consensus: Strong Buy